Madrigal Pharmaceuticals recently announced an exclusive global license agreement with Pfizer for ervogastat, an oral DGAT-2 inhibitor targeting MASH, with more details shared at the 44th Annual J.P.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback